TORONTO, ON – March 27, 2019 – CB2 Insights (CSE:CBII) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has initiated integration with Premier Health Group (CSE:PHGI), a leading Electronic Medical Records (EMR) platform.
The agreement will give the more than 4,600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific Clinical Decision Support (“CDS”) tool. CB2 Insights’ CDS tool is designed to help healthcare providers considering integrating medical cannabis into a patient’s treatment plans. This first-of-its-kind integration in the sector will allow physicians and healthcare practitioners to overcome many of the barriers they face from a lack of access to medical cannabis education, qualification factors, risk factors and benefits on a patient-by-patient basis using clinically-led, evidence-based data.
“For the past 4 years, we have worked toward simplifying the process for a physician to determine the appropriateness and potential efficacy of medical cannabis as an option within a patient’s treatment plan,” said Prad Sekar, CEO of CB2 Insights. “We are now in a position to benefit from the aggregated and anonymized data gathered from more than 300,000 patient visits in a clinical environment along with the hundreds of clinical trials and observational studies that are collectively used to power our CDS tool. Clinicians can use this point-of-care application to help them incorporate cannabis as a treatment option into their practice and create improved access for patients who can benefit from cannabinoid therapy.”
CB2 Insights, through its clinical arm in the U.S., operates 28 medical cannabis evaluation centers staffed with physicians and healthcare practitioners and creates access for patients who qualify for medical cannabis as well as a center of excellence to study and understand the clinical outcomes of cannabinoid therapy. CB2 gathers data at the point-of-care in a HIPAA-compliant manner, both aggregated and anonymized, to study trends and outcomes that work to educate and support stakeholders including but not limited to physicians and other healthcare professionals.
“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO of Premier Health. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”
As part of the agreement, CB2 will provide the development and continuous maintenance and support of the CDS tool and all related technologies. Premier Health will support the partnership by providing access to their software and will engage its network of physicians and other healthcare professionals to assist in the adoption of the CDS tool.
